Having a better understanding of what things are associated with LCHADD retinopathy can provide insight towards developing treatment. During this presentation, Dr. Gillingham will provide an update on the current results of a natural history study of 40 patients with LCHADD. She will also discuss what factors are associated with retinal structure and function, and how blood biomarkers or genetics might be related. Lastly, Dr. Gillingham will update our FAOD community about her lab’s efforts to treat retinopathy in an LCHADD mouse.
The MitoAction committee chairs met by conference call to discuss the exciting ideas and projects ahead for 2008.
Greg Macpherson, CEO of MitoQ, discusses “Mitochondria and MitoQ: A Research Update.” MitoQ’s mission is to raise awareness of mitochondria and the link between...
It's time to take charge of the many hours that we as patients and families spend in clinics, waiting rooms, hospitals, and healthcare provider...
